Following U.S. FDA Approval, Glenmark Plans Multi-Geography Launches For Crofelemer
This article was originally published in PharmAsia News
India’s Glenmark has sped up its regulatory filings in a large set of countries, enthused by the prospects of filling unmet needs for HIV treatment regimens.
You may also be interested in...
Glenmark Steps Closer To First NCE With Positive Phase II Data For Crofelemer; Gears Up For Larger Trials
MUMBAI - Years of racing to put an original compound into the market looks set to be one step closer for India's Glenmark Pharmaceuticals as the company announced successful completion of Phase II multi-center clinical trials in India for its first-in-class anti-diarrheal agent crofelemer
"We Have Gone Through Hardships But Our Passion Remains High," Says Glenn Saldanha, Managing Director, Glenmark Pharma: An Interview With PharmAsia News (Part 2 of 2)
Glenn Saldanha, Managing Director, Glenmark Pharmaceuticals has been speaking about discovery research in India for more than a decade but his critics from bigger companies played down those efforts as high decibel talk, over-ambitious thoughts and a few even called them day dreaming moves. But five out-licensing deals in seven years with companies like Eli Lilly, Merck Serono and Sanofi-Aventis have transformed the way Glenmark Pharma is seen by the world today (PharmAsia News, May 3, 2010).
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.